|
|||||
|
|
A phase 1 dose‐escalation study of XmAb®2513 in patients with relapsed or refractory Hodgkin lymphoma |
|
| Authors: | Anita Kumar Kristie A. Blum Henry C. Fung Mitchell R. Smith Paul A. Foster Anas Younes |
| Affiliation: | 1. Memorial Sloan‐Kettering Cancer Center, New York, NY, USA;2. Ohio State University, Columbus, OH, USA;3. Rush University Medical Center, Chicago, IL, USA;4. Fox Chase Cancer Center, Philadelphia, PA, USA;5. Xencor, Inc., Monrovia, CA, USA;6. MD Anderson Cancer Center, Houston, TX, USA |
| Abstract: | |
| Keywords: | Hodgkin lymphoma monoclonal antibodies clinical trials therapy immunotherapy |